Sandoz this week introduced its calcipotriene and betamethasone dipropionate ointment in the United States. It will be the first generic version of Leo Pharma’s Taclonex ointment in the market.
Calcipotriene and betamethasone dipropionate ointment, the first generic version of Leo Pharma’s Taclonex ointment, was launched in the United States by Sandoz.
Talconex is a vitamin D analogue and corticosteroid combination product used to treat adults with psoriasis vulgaris, which affects approximately 2% of the US population.
“Sandoz is proud to be first-to-market with a generic version of this important therapy,” said Peter Goldschmidt, president of Sandoz US. “This launch further broadens our strong offering of differentiated generic dermatology products.”
Tolmar Inc. owns the Abbreviated New Drug Application for the product and received FDA approval for a generic version. Sandoz will market its calcipotriene and betamethasone dipropionate ointment in partnership with Tolmar.
Talconex produced $96 million in US sales in 2013, according to IMS Health. Sandoz’s generic version will be available in 60-g and 100-g tubes.
Get the latest industry news, event updates, and more from Managed healthcare Executive.
PBM-Offered Genomics Testing Could Reshape Prescribing of Medications
July 25th 2025Two PBMs, True Rx Health Strategies and Capital Rx, are using pharmacogenomics — how a person’s DNA affects their response to medications — to reduce the trial-and-error of prescribing medications, saving employers and patients time and money.
Read More
FDA Extends Review of Blenrep Combinations in Multiple Myeloma
July 24th 2025Last week, an FDA advisory committee against the risk-benefit profile of Blenrep in combination with other therapies. Regulators and reviewers were concerned about the ocular side effects and dosing and tolerability. The new action date is Oct. 23, 2025.
Read More
Sarepta to Pause Shipments of the Gene Therapy Elevidys
July 22nd 2025Sarepta officials said the temporary halt in shipments was done to maintain a productive working relationship with regulators while they address a safety labeling update about the risk of acute liver disease related to Elevidys.
Read More